At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
BR55drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2
In Brief
A Phase 2 clinical trial evaluating BR55 for Prostate Cancer. Completed, enrolled 19 participants across 2 sites in 2 countries.
Detailed Summary
Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason Score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesFrance, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartAug 2014
Primary CompletionJul 2015
Study CompletionJan 2016
TodayJul 2026
First PostedMay 20, 2014
Enrollment StartAug 1, 2014
Primary CompletionJul 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.1 years ago
Interventions
BR55drug
Ultrasound contrast agent